Voyager Therapeutics Stock Forecast
NASDAQ: VYGRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 8, 2:45 PM ET
VYGR analyst consensus
Consensus (11 analysts)
strong_buy
Avg. price target
$14.89+529.60%
- Strong buy 0
- Buy 11
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 11 Wall Street analysts covering Voyager Therapeutics (2026-10-08), 11 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $14.89, with a high estimate of $25.00 and a low estimate of $8.00. The average target implies upside of 529.6% from the current price of $2.37.
The spread between the highest and lowest targets is 212.5%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for VYGR.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 11 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $8.00 | +238.27% |
| Average target | $14.89 | +529.60% |
| High target | $25.00 | +957.08% |